Highlights and Quick Summary
- Capex/Depreciation for the quarter ending March 31, 2022 was -0.08 (a -97.02% decrease compared to previous quarter)
- Year-over-year quarterly Capex/Depreciation decreased by -81.14%
- Annual Capex/Depreciation for 2021 was -1.49 (a -46.25% decrease from previous year)
- Annual Capex/Depreciation for 2020 was -2.78 (a -49.62% decrease from previous year)
- Annual Capex/Depreciation for 2019 was -5.52 (a 386.83% increase from previous year)
- Twelve month Capex/Depreciation ending March 31, 2022 was -1.35 (a -9.54% decrease compared to previous quarter)
- Twelve month trailing Capex/Depreciation increased by 218.02% year-over-year
Trailing Capex/Depreciation for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| -1.35 | -1.49 | -0.71 | -0.43 |
Visit stockrow.com/PHAS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Capex/Depreciation of PhaseBio Pharmaceuticals
Most recent Capex/Depreciationof PHAS including historical data for past 10 years.Interactive Chart of Capex/Depreciation of PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals Capex/Depreciation for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | -0.08 | – | – | – | – |
| 2021 | -2.73 | -4.91 | -0.43 | -0.28 | -1.49 |
| 2020 | -0.16 | -3.24 | -9.14 | -12.19 | -2.78 |
| 2019 | -2.72 | -7.9 | -8.02 | -2.71 | -5.52 |
| 2018 | -3.83 | -0.11 | -0.81 | -0.22 | -1.13 |
| 2017 | – | – | -0.43 | -3.0 | -2.25 |
| 2016 | – | – | – | – | 0.0 |
Business Profile of PhaseBio Pharmaceuticals
Sector: Healthcare
Industry: Biotechnology